Compare Amgen, Inc. (AMGN) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while iShares 20 Plus Year Treasury Bond ETF trades at $84.34. The key difference: Amgen, Inc. pays a 2.77% dividend while iShares 20 Plus Year Treasury Bond ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | TLT | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | — |
52-Week High | $388.16 | $92.06 |
52-Week Low | $271.18 | $83.02 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $84.47, showing minimal daily movement with a slight decline of 0.02%. Technical indicators signal a bearish trend, while recent news highlights investor comparisons with other bond ETFs amid fluctuating Treasury yields. The ETF maintains consistent dividend distributions, with recent payouts in 2026, but lacks disclosed fundamental ratios like P/E or ROE, focusing instead on its role in long-term U.S. government debt exposure.
The outlook for TLT hinges on interest rate trends and economic data, with potential gains if the Fed cuts rates but risks from persistent inflation or further hikes. Investor sentiment is mixed, weighing high yields against duration risk, making it sensitive to macroeconomic shifts rather than company-specific fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
